How IL-6/STAT3 helps CIC-DUX4 sarcoma spread and hide from the immune system
The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression
Researchers will target the IL-6/STAT3 signaling pathway in CIC-DUX4 fusion sarcoma to look for ways to stop cancer spread in children and young adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11311805 on NIH RePORTER |
What this research studies
This project studies an aggressive childhood sarcoma driven by the CIC-DUX4 fusion and focuses on a cell signal called IL-6/STAT3 that appears to help tumors survive, change their metabolism, and attract immune cells that suppress anti-cancer responses. Scientists will use laboratory models, tumor specimens, and animal experiments to see how the fusion protein turns on IL-6/STAT3 and how that affects cancer stem-cell features and lipid metabolism. The team will also examine how tumors recruit tumor-associated macrophages and immunosuppressive T cells and test whether blocking IL-6/STAT3 reverses these effects. Results could point to treatments that reduce metastasis and restore anti-tumor immunity for young patients with this fusion-positive sarcoma.
Who could benefit from this research
Good fit: Children, adolescents, and young adults diagnosed with CIC-DUX4 fusion-positive sarcoma would be the most relevant candidates for related trials or sample donation.
Not a fit: Patients who have other types of sarcoma without the CIC-DUX4 fusion or unrelated cancers are unlikely to benefit directly from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to therapies that block IL-6/STAT3 signaling and reduce metastasis and immune suppression in children and young adults with CIC-DUX4 sarcoma.
How similar studies have performed: Targeting IL-6/STAT3 has shown promise in some other cancer types, but applying this approach specifically to CIC-DUX4 fusion sarcoma is new and not yet tested in patients.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Yu, Hua E — Beckman Research Institute/city of Hope
- Study coordinator: Yu, Hua E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.